



HAL
open science

A sensitised mutagenesis screen in the mouse to explore the bovine genome: study of muscle characteristics

Laetitia Magnol, Olivier Monestier, Karine Vuillier-Devillers, S. Wagner,
Olivier Cocquempot, M.C. Chevallier, Véronique V. Blanquet

► To cite this version:

Laetitia Magnol, Olivier Monestier, Karine Vuillier-Devillers, S. Wagner, Olivier Cocquempot, et al.. A sensitised mutagenesis screen in the mouse to explore the bovine genome: study of muscle characteristics. *Animal*, 2011, 5 (5), pp.663-671. 10.1017/S1751731110002405 . hal-01211944

HAL Id: hal-01211944

<https://hal.science/hal-01211944v1>

Submitted on 29 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A sensitised mutagenesis screen in the mouse to explore the bovine genome: study of muscle characteristics

L. Magnol¹, O. Monestier¹, K. Vuillier-Devillers¹, S. Wagner², O. Cocquempot¹,
M. C. Chevallier¹ and V. Blanquet^{1†}

¹UMR1061-INRA, Unité de Génétique Moléculaire Animale, Université de Limoges, 87060 Limoges, France; ²Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Experimental Genetics, 85764 Neuherberg/Munich, Germany

(Received 5 March 2010; Accepted 28 August 2010; First published online 10 December 2010)

Meat yield and quality are closely related to muscle development. The muscle characteristics mainly take place during embryonic and postnatal phases. Thus, genetic control of muscle development in early stages represents a significant stake to improve product quality and production efficiency. In bovine, several programmes have been developed to detect quantitative trait loci (QTL) affecting growth, carcass composition or meat quality traits. Such strategy is incontestably very powerful yet extremely cumbersome and costly when dealing with large animals such as ruminants. Furthermore, the fine mapping of the QTL remains a real challenge. Here, we proposed an alternative approach based on chemical mutagenesis in the mouse combined with comparative genomics to identify regions or genes controlling muscle development in cattle. At present, we isolated seven independent mouse lines of high interest. Two lines exhibit a hypermuscular phenotype, and the other five show various skeletomuscular phenotypes. Detailed characterisation of these mouse mutants will give crucial input for the identification and the mapping of genes that control muscular development. Our strategy will provide the opportunity to understand the function and control of genes involved in improvement of animal physiology.

Keywords: animal models, mutagenesis, myostatin, muscle development, cattle

Implications

The empirical selection of phenotypic traits of economic interest carried out by the bovine breeders will be assisted gradually by the exploitation of knowledge concerning the bovine genome. However, such a revolution in the methods of selection henceforth presents several difficulties. To speed up the identification of genes controlling the musculoskeletal functions in cattle, we have set up a chemical mutagenesis programme based on a sensitised screen using the *Gdf8* knockout mouse as genetic background to assess skeletal muscle hypertrophy. The increased understanding of gene's function in the mouse is undeniably bringing a wealth of information that, when combined with comparative genomics, can accelerate our knowledge on the bovine genome. Our strategy led to the identification of new mouse mutants displaying defects in the muscle and skeleton. Detailed characterisation of these selected mutants might unravel new pathways or genes involved in physiological functions. We might provide the molecular means for a next generation

of marker-assisted or gene-assisted selection in livestock populations to improve product quality and competitiveness.

Introduction

Comparing genomes provides a tremendous insight into the biology of the organisms and constitutes a major resource to reveal functionally conserved regions. With the annotation of the human and mouse genome sequences and the availability of the sequence of the bovine genome, cattle genomics research is greatly accelerating. It allows to carry out phenotypic and functional analyses of orthologous genes in the mouse, the major model organism for the study of mammalian genomes. Thus, the causal mutations for double-muscling in cattle were identified based on mouse model in which *Gdf8* was knocked out, producing in mouse a similar phenotype as the one observed in several cattle breeds (McPherron and Lee, 1997; Grobet *et al.*, 1997, 1998 and 2003). For several genetic disorders in cattle, the existence of a mouse mutant associated with similar phenotypes in human were important keys to discover the relevant gene, as in Chediak–Higashi syndrome (Kunieda *et al.*, 2000), chondrodysplastic dwarfism

† E-mail: veronique.blanquet@unilim.fr

(Takeda *et al.*, 2002), anhidrotic ectodermal dysplasia (Drögemüller *et al.*, 2001) and more recently syndactyly (Duchesne *et al.*, 2006). Similarly, a mouse knockout for *Dgat1* gene was the starting point for the discovery of a mutation in the bovine gene and its effect as quantitative trait loci (QTL) for milk fat content. Large-scale mutagenesis strategies produce comprehensive collections of mouse mutations allowing the identification of effector genes in a systematic, efficient and high-throughput manner. In particular, phenotype-driven mutagenesis programmes using chemical *N*-ethylnitrosourea (ENU) have led in the past years to a rich worldwide collection of mutant lines, essential for systematic and comprehensive gene function studies of the mouse genome (Soewarto *et al.*, 2009). The primary premise behind a phenotype-driven approach such as ENU mutagenesis is that it allows an unbiased investigation of the genetic bases of a heritable trait. Both the identification of the biological consequences of mutations in uncharacterised genes and the assignment of novel roles to previously studied genes have been highlighted. In many cases, the connection between cloned genes and mutant phenotypes is unexpected, supporting the use of an analytical strategy that is not biased by presumptions with regard to gene functions. The ENU mutagenesis efficiently creates point mutations in spermatogonial stem cells (Guenet, 2004) that usually have effects on single genes. The identification of a mutated gene is only dependent on the screening process set up for a given variable trait. Moreover, ENU mutagenesis has the potential to create an exclusive collection of loss- and gain-of-function mutations, providing a range of phenotypes.

Taking advantage of the power of comparative genomics to speed up the identification of genomic regions or genes controlling the musculoskeletal functions in farm animal, especially cattle, we set up an ENU-sensitised programme to isolate new mutations in mouse leading to muscle or bone phenotypes. As it has been successfully shown in lower organisms such as *Drosophila melanogaster*, *Caenorhabditis elegans* and *Saccharomyces cerevisiae* (Loo *et al.*, 1995; Raftery *et al.*, 1995; Bach *et al.*, 2003), modifier chemical mutagenesis screens are powerful genetic tools to define the relative contribution of signalling interactions to physiological processes. Recently, such a sensitised genetic system has been developed in mouse allowing a similar dissection of mammalian signalling pathways (Satterthwaite *et al.*, 2000; Carpinelli *et al.*, 2004; Rubio-Aliaga *et al.*, 2007; Buac *et al.*, 2008). In a commonly used type of genetic screen, organisms carrying a defined mutation affecting the process of interest are further mutagenised and screened for second-site mutations, or modifiers, that enhance or suppress the severity of the parental phenotype (Simon *et al.*, 1991; Karim *et al.*, 1996). The initial mutation often renders the system responsive to subtle changes in modifiers that would not be penetrant on a wild type background. This sensitivity often permits a dominant screen, decreasing the time and resources required to identify new mutations.

In this study, we designed a sensitised ENU modifier screen using the mutant mouse model with defects in the myostatin/*Gdf8* gene, which is critical for the normal muscle

development (Grobet *et al.*, 2003). Mice lacking the *myostatin* gene have a widespread increase in skeletal muscle mass resulting from a combination of muscle fibre hypertrophy and hyperplasia associated with alterations of haematological and biochemical blood parameters. This phenotype presents significant similarities to the double-muscling seen in cattle (Arthur, 1995; Bellinge *et al.*, 2005). Mutants also show a decrease in the subcutaneous fat and a generalised increase in bone density and strength (Elk-asrawy and Hamrick, 2010). Unlike the majority of sensitised screens in mouse in which direct mutagenesis of knockout males that are deficient in a key gene are used, we choose to ENU-treat wild type C57BL/6J males. The rationale behind our design is based on the hypermuscular phenotype of the *Gdf8*^{-/-} mice, which may interfere with the efficiency of the *in vivo* mutagenesis. Furthermore, generating F1 animals heterozygous at the *Gdf8* locus may allow us to highlight low changes not revealed on a wild type background.

We screened about 3000 individuals in the F1 progeny that carry heterozygous mutations induced by ENU, and identified seven independent lines of high interest. Two lines exhibit a hypermuscular phenotype, the other five show various skeletomuscular phenotypes. Functional analyses are currently being undertaken. As far as we can tell, most of the mutagenesis programmes have focused up to now on the location of mutations linked to human diseases (Clark *et al.*, 2004; Cordes, 2005) and none has been oriented towards the improvement of traits for domestic animals. These new mouse mutant lines will provide significant information about modifiers of the *Gdf8* signalling pathway.

Material and methods

Sensitised ENU mutagenesis

Male C57BL/6J mice were purchased from Charles River (Germany). *Gdf8* knockout mice were a generous gift from L. Grobet (University of Liège, Belgium). They were generated on a mixed background of 129/Sv and CD1 mice and subsequently backcrossed 17 times to FVB strain (Grobet *et al.*, 2003). All the mice were bred and housed under specific pathogen free conditions in The Limoges University animal facility according to international ethical guidelines. The housing room was maintained on a 12 h light/dark cycle. C57BL/6J males (10 to 12 weeks old) were injected intraperitoneally with three weekly doses of 90 mg/kg ENU (Serva, Heidelberg, Germany) as previously described (Soewarto *et al.*, 2003).

Efficiency of the *in vivo* mutagenesis is scored by the period of sterility that follows the ENU treatment. Only F0 ENU-treated males displaying a period of sterility (period between the last ENU injection and the calculated time of conception) of more than 65 days have been used to breed with *Gdf8*^{-/-} homozygous females to obtain the F1 progeny.

Phenotypic screening

The F1 offspring, transheterozygote animals carrying heterozygous mutations induced by ENU and a mutated allele for *Gdf8*, were screened through a series of morphological

and physiological parameters. After weaning, in parallel to a morphological study derived from the SHIRPA protocol (Rogers *et al.*, 1997; Brown *et al.*, 2005), weight and body size measurements are recorded every 3 days the first month, then every week till 10 weeks. These tests allow us to estimate both overall adiposity and the set of musculature, especially the development of hind- and forelimb muscle mass. Blood count test and clinical chemistry analyses were performed at 6 and 8 weeks, respectively. Haematology parameters were evaluated using an automated haematological analyser (ABC Vet, Scil, Altorf/Strasbourg, France). The blood (50 μ l) was collected in EDTA-coated tubes. Blood biochemical explorations including 26 parameters (uric acid, albumin, alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase, total bilirubin, calcium, cholinesterase, cholesterol, creatine kinase, creatine

kinase-MB, creatinine, gamma-glutamyl transpeptidase, glucose, iron, HDL/LDL-cholesterol, lactate, lactate dehydrogenase, magnesium, phosphorus, transferrin, triglycerides, urea and total proteins) were measured. Mice were fasted overnight (16 h) for blood collection on the following morning. Blood samples (500 μ l) were collected in lithium heparin tubes under isoflurane anaesthesia by retro-orbital puncture following recommended ethical guidelines. After centrifugation, plasmatic analyses were performed using a KONELAB 30 automat (Thermo scientific, Cergy Pontoise, France) on the day of collection. To identify phenotypic variants, we collected normative data from C57BL/6J control mice ($n = 40$), FVB control mice ($n = 40$) and C57BL/6J \times FVB mixed background mice ($n = 40$). Mice with at least one parameter ≥ 2.5 s.d. above or ≥ 2.5 s.d. below the mean of the control mice were defined as phenotypic variants, and considered as putative candidates for further examination. Statistics were calculated with a Student's *t*-test. If a variant was identified in the haematological or clinical chemistry screening, measurements were repeated 2 weeks after the first analysis to confirm the phenotype.




Figure 1 Design of the sensitised genetic screen. To identify modifier mutations that interact with the *Gdf8* signalling pathway, we used myostatin knockout mutant mice (denoted by *Gdf8*^{-/-} allele). The ENU-treated C57BL/6J wild type males were bred with *Gdf8*^{-/-} females (FVB genetic background). The F1 progeny was subjected to a defined phenotypic screen. Interesting F1 variants were tested for inheritance of the phenotype by backcrossing to *Gdf8*^{-/-} animals. G2 animals were then phenotyped. ENU mutation is marked as 'a' locus; ENU = N-ethylnitrosourea.

Confirmation cross

Any phenovariant showing parameters above or below 2.5 s.d. of the mean is considered as interesting for further study. The Mendelian inheritance of the trait needs first to be confirmed by mating mutant animals with *Gdf8*^{-/-} mice. These G2 animals, checked for the mutated phenotype are used to both map the genomic region and to refine the phenotypic analyses.

Mapping

A panel of 60 MIT polymorphic markers between FVB and C57BL/6J was used for a genome-wide linkage analysis as previously described by Besson *et al.* (2005). PCR amplifications of microsatellite markers were carried out on DNA from G2 or G3 affected animals, leading to the map of a chromosomal region to an approximately 30 cM interval. Further fine mapping was performed using more closely spaced markers.

Results

ENU mutagenesis screen for modifiers of the *Gdf8* phenotype

The strategy of our ENU-sensitised screen is shown in Figure 1. Since the beginning of our project, a total of 136 C57BL/6J mice were injected with 90 mg/kg ENU in three weekly

Table 1a Inheritance testing of F1 animals with abnormal phenotypes CC

| | Clinical Chemistry | Morphology | Haematology | Total |
|---------------------------|--------------------|------------|-------------|-------|
| Total F1 screened | 2250 | 3000 | 3000 | — |
| Number of phenovariants | 26 | 20 | 3 | 49 |
| CC set up | 26 | 20 | 3 | 49 |
| Confirmed mutants | 2 | 6 | 1 | 9 |
| CC in progress | 19 | 9 | 0 | 28 |
| No Mendelian transmission | 5 | 5 | 2 | 12 |

CC = confirmation cross.

Table 1b Mutant lines generated in *Gdf8* modifier dominant screen

| | Line name | Variant phenotype |
|---------------------|-----------------|--|
| Haematology | AIF15 | Red cell distribution width high |
| | GMA03 | High mean red cell volume |
| | EEF06 | High mean corpuscular haemoglobin |
| Morphology | GMA21 | Hair loss |
| | GMA18 | Huge eyes |
| | GMA25 | Huge eyes |
| | FF07 | Cataract |
| | CEF01 | Cataract |
| | GMA24 | Kinky tail, tail ring |
| | GMA12 | Kinky tail, short tail, tailless |
| | GMA11 | Kinky tail, short tail, tailless |
| | CEF01 | Kinky tail tip |
| | ANM08 | Kinky tail |
| | AKM02 | Kinky tail |
| | GMA35 | Kinky tail, short tail, tailless |
| | Cut | Kinky tail |
| | GMA50 | Kinky tail |
| | DJM09 | Kinky tail tip |
| | GMA48 | Kinky tail |
| | NF02 | Muscle increase |
| AIM09 | Muscle increase | |
| DVM16 | Muscle increase | |
| Biochemistry | | |
| Muscular parameters | GMA06 | Creatinine high, muscle increase |
| | GMA45 | Creatinine high, muscle increase |
| | GMA15 | Lactate high |
| Lipids | ATM02 | Hypercholesterinaemia |
| | BRM04 | Triglycerides high |
| | BTF10 | Triglycerides high |
| | COM74 | Triglycerides high |
| | CUM26 | Triglycerides high |
| | CYF26 | Triglycerides high |
| | ATM02 | LDL level high |
| | BBM18 | HDL level low |
| Electrolytes | VM01 | Magnesium high |
| | CJF10 | Phosphorus low |
| Liver enzymes | DWF15 | Aspartate aminotransferase activity high |
| | EEM17 | Amylase activity high |
| | EAM17 | Alanine aminotransferase activity high |
| | AAF03 | Alkaline phosphatase activity high |
| | CLM01 | Bilirubin total |
| Nitrogen elements | EHF31 | Urea level high |
| | DKF02 | Urea level high |
| | COF68 | Urea level low |
| | BTM10 | Uric acid high |
| | BRF07 | Uric acid high |
| Others | DKF07 | Cholinesterase activity low |
| | GMA02 | Hyperglycaemia |
| | BDM02 | Transferrin level high |

doses. Thirty ENU males (22%) were excluded because they were sterile or the sterility period was <65 days, and therefore it would not ensure that the F1 offspring would derive from ENU-exposed spermatogonial stem cells. By breeding the ENU-injected males with *Gdf8*^{-/-} female mice, we generated about 3000 F1 mice that underwent the

phenotyping workflow. We identified 48 abnormal phenotypes that have been successively put in confirmation cross. Nine confirm the Mendelian inheritance of the phenotype, 28 are still under investigation, and 11 do not transmit the phenotype or died before transmission (Table 1). At present, we focus our study on seven lines. Incorporation of two

Table 2 Muscle development in Gdf8 knockout mice

| Brachii triceps muscle mass ($\times 10^{-3}$ g) | WT | Gdf8 ^{+/-} | Gdf8 ^{-/-} | P-value | |
|---|-----------------|---------------------|---------------------|------------------------|--|
| | | | | WT/Gdf8 ^{-/-} | Gdf8 ^{+/-} /Gdf8 ^{-/-} |
| 3 weeks | | | | | |
| Male | 26.6 \pm 7.0 | 28.7 \pm 4.4 | 48.7 \pm 10.7 | * | * |
| Female | 23.0 \pm 3.4 | 24.4 \pm 3.9 | 46.7 \pm 5.6 | *** | ** |
| 20 weeks | | | | | |
| Male | 91.7 \pm 6.5 | 176.4 \pm 20.8 | 254.4 \pm 18.3 | *** | * |
| Female | 77.6 \pm 11.6 | 132.2 \pm 22.0 | 195.8 \pm 33.0 | ** | * |

WT = wild type.

Triceps muscles from 3- or 20-week-old mice were collected and weighed. Each value ($n = 5$) represents the mean \pm s.e.m.

P-value from two-sample *t*-test: *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$.

Table 3 Comparison of clinical chemistry parameters between heterozygous Gdf8^{+/-} homozygous Gdf8^{-/-} and WT mouse littermates

| Clinical chemistry | WT ($n = 56$) Mean \pm s.e.m. | Gdf8 ^{-/-} ($n = 36$) Mean \pm s.e.m. | Gdf8 ^{+/-} ($n = 21$) Mean \pm s.e.m. | P-value | |
|----------------------------|--------------------------------------|---|---|------------------------|--|
| | | | | WT/Gdf8 ^{-/-} | Gdf8 ^{+/-} /Gdf8 ^{-/-} |
| Muscular parameters | | | | | |
| Creatinine | 6.96 \pm 1.63 | 13.1 \pm 1.3 | 7.24 \pm 1.50 | *** | *** |
| Lactate | 2277 \pm 744 | 2119 \pm 357 | 3006 \pm 1327 | | * |
| Lactic dehydrogenase | 448 \pm 158 | 502 \pm 103 | 372 \pm 215 | | |
| CK | 184 \pm 112 | 208 \pm 106 | 194 \pm 135 | | |
| CKMB | 258 \pm 117 | 284 \pm 98 | 206 \pm 113 | | |
| Lipids | | | | | |
| Cholesterol | 3.54 \pm 0.83 | 3.92 \pm 0.56 | 2.98 \pm 0.77 | * | *** |
| Triglycerides | 2.19 \pm 0.63 | 1.63 \pm 0.35 | 1.63 \pm 0.35 | *** | ** |
| LDL | 0.29 \pm 0.09 | 0.27 \pm 0.07 | 0.25 \pm 0.08 | | |
| HDL | 3.02 \pm 0.71 | 3.39 \pm 0.51 | 2.66 \pm 0.68 | * | ** |
| Electrolytes | | | | | |
| Calcium | 2.49 \pm 0.10 | 2.62 \pm 0.10 | 2.31 \pm 0.29 | ** | *** |
| Magnesium | 0.84 \pm 0.08 | 0.75 \pm 0.04 | 0.89 \pm 0.17 | ** | *** |
| Phosphorus | 1.83 \pm 0.18 | 2.1 \pm 0.19 | 1.81 \pm 0.33 | *** | ** |
| Liver enzymes | | | | | |
| sGOT | 65 \pm 21 | 86.9 \pm 16.3 | 62.7 \pm 18.1 | *** | ** |
| Amylase | 3998 \pm 552 | 4492 \pm 822 | 3438 \pm 593 | * | *** |
| sGPT | 41 \pm 11 | 49.9 \pm 11.8 | 42 \pm 11.1 | * | |
| Alkaline phosphatase | 113 \pm 23 | 155 \pm 32 | 123 \pm 38 | *** | * |
| Bilirubin total | 2.73 \pm 0.89 | 2.84 \pm 0.52 | 2.36 \pm 0.69 | | |
| Nitrogen elements | | | | | |
| Urea | 9.42 \pm 0.93 | 9.88 \pm 1.45 | 9.86 \pm 1.72 | | |
| Uric acid | 33.3 \pm 15.5 | 43.1 \pm 14.1 | 25 \pm 13.6 | | * |
| Protein | | | | | |
| Protein total | 54.3 \pm 2.6 | 57.4 \pm 2.9 | 50.5 \pm 8.3 | *** | * |
| Albumin | 30.4 \pm 1.3 | 32.8 \pm 1.5 | 28.8 \pm 4.1 | *** | ** |
| Others | | | | | |
| Cholinesterase | 1347 \pm 389 | 1669 \pm 342 | 972 \pm 366 | *** | *** |
| Glucose | 8.80 \pm 2.40 | 7.13 \pm 1.14 | 10.4 \pm 3.86 | *** | ** |
| Iron total | 29.5 \pm 4.2 | 31.7 \pm 4.2 | 32.2 \pm 9.9 | | |
| Transferrin | 1.2 \pm 0.1 | 1.24 \pm 0.06 | 1.08 \pm 0.15 | *** | ** |
| HBDH | 87.1 \pm 29.3 | 104.5 \pm 21.4 | 58 \pm 19.5 | * | *** |

WT = wild type; CK = creatine kinase; CKMB = creatine kinase MB; LDL = low density lipoprotein; HDL = high density lipoprotein; sGOT = serum glutamoxaloacetate transferase; sGPT = serum glutamopyruvate transferase; HBDH = hydroxybutyrate deshydrogenase.

P-value from two-sample *t*-test: *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$.

different inbred strains in our screen allows efficient mapping of the C57BL/6J mutagenised allele possible by subsequent crosses to FVB.

Gdf8 mutant phenotype

We characterised the phenotype of adult heterozygous and homozygous Gdf8^{-/-} knockout mice in detail to be able to

Table 4 Comparison of haematological parameters between homozygous *Gdf8*^{-/-} mice and WT littermates

| | WT (n = 28) mean ± s.e.m. | <i>Gdf8</i> ^{-/-} (n = 32) mean ± s.e.m. | P-value |
|--------------------------------|------------------------------|--|---------|
| RBC (10 ⁶ /μl) | 9.9 ± 0.6 | 9.0 ± 0.5 | *** |
| Hb (g/dl) | 16.8 ± 0.1 | 16.1 ± 0.8 | * |
| Hct (%) | 55.3 ± 3.4 | 53.2 ± 2.6 | |
| MCV (fl) | 55.8 ± 0.9 | 59.4 ± 1.2 | *** |
| MCHC (g/dl) | 30.4 ± 0.7 | 30.2 ± 0.5 | |
| MCH (pg) | 17.0 ± 0.4 | 17.9 ± 0.5 | *** |
| RCDW (%) | 11.4 ± 0.4 | 12.2 ± 0.6 | *** |
| Platelet (10 ³ /μl) | 1853 ± 285 | 1954 ± 258 | |
| MPV (fl) | 4.9 ± 0.1 | 4.8 ± 0.1 | ** |
| WBC (10 ³ /μl) | 9.0 ± 0.9 | 10.6 ± 1.9 | ** |

RBC = red blood cells; Hb = haemoglobin; Hct = haematocrit; MCV = mean corpuscular volume; MCHC = mean corpuscular haemoglobin concentration; MCH = mean corpuscular haemoglobin; RCDW = red cell distribution width; MPV = mean platelet volume; WBC = white blood cells.

P-value from two-sample t-test: ****P* < 0.001; ***P* < 0.01; **P* < 0.05.




Figure 2 Characterisation of the GMA06 phenotype. Top: plasmatic creatinine levels from homozygous *Gdf8* GMA06 mutant, wild type and homozygous *Gdf8*^{-/-} mice. Bottom: increased skeletal muscle mass in GMA06 mutant compared to wild type and homozygous *Gdf8*^{-/-} mice. (a) pectoral muscles (b) lower limb (c) upper limb and neck of skinned animals.

identify ENU-modified phenotypes from the original *Gdf8*^{-/-} ones. As described by McPherron *et al.* (1997), *Gdf8*^{-/-} mice show a large and widespread increase in skeletal muscle mass, resulting from a combination of muscle cell hyperplasia

and hypertrophy. This phenotype is more obvious in males than in females. In heterozygous *Gdf8*^{+/-} mice, we observed an age-related hypermuscular phenotype. Until 5 months old, *Gdf8*^{+/-} animals are not distinguishable from the wild type, and subsequently they have a greater muscle development, although less pronounced than in homozygous *Gdf8*^{-/-} mice (Table 2). Both genotypes were analysed for clinical chemistry and basic haematology parameters. Out of the 26 clinical chemical parameters, 17 were significantly different in *Gdf8*^{-/-} animals compared to wild type littermates, including 10 with a *P*-value < 0.001 (Table 3). It is known that creatinine and glucose levels in blood rise under certain circumstances, such as muscle mass increase. As expected, higher blood levels of creatinine and glucose were observed in *Gdf8*^{-/-} mice. Plasma alkaline phosphatase activity and phosphorus content increased in homozygous animals compared to their wild type littermates. Triglyceride concentration significantly decreased in both *Gdf8*^{-/-} and *Gdf8*^{+/-} mice. All these differences were taken into account when screening for phenovariants in our sensitised screen. In addition, a significant lower number of red blood cells were found in *Gdf8*^{-/-} mice compared to wild type. This change is associated with higher mean corpuscular values (Table 4).

Skeletomuscular phenotypes

The seven mutant lines of major interest showed either altered creatinine levels (GMA06 and GMA45) or skeletal defects (Cut, GMA11, GMA12, GMA24 and GMA35). All the other mutant lines were cryopreserved. In the GMA06 mutant line, animals present high levels of plasma creatinine associated with a hypermuscular phenotype (Figure 2). GMA06 males weigh approximately 43% more than control FVB or FVB × C57BL/6J wild type mice and 21% more than FVB *Gdf8*^{-/-} mice. This weight difference is less pronounced in GMA06 females compared to FVB *Gdf8*^{-/-} mice (~15%). We carried out a preliminary rough mapping of the mutation in GMA06. The identified mutation shows a linkage to the chromosome 13 in an interval of 8 cM, in between D13Mit288 and D13Mit76 markers. The GMA45 mutant line is still under investigation. A more detailed phenotypic and molecular analysis may reveal parallelisms with the former line.

The four lines Cut, GMA11, GMA12 and GMA35 display different malformations of the skeleton such as fusion of sacral or caudal vertebrae and absence of several lumbar vertebrae. All mice exhibit variable expressivity in tail phenotypes, ranging from kinked tails of various degrees, to short tails and even no tails. An interesting observation in this study was provided by genotype–phenotype correlation in GMA11 and GMA12 mice. Their phenotype is always more severe when mice are homozygous at the *Gdf8* locus. Haematological and clinical chemistry parameters did not vary in these four lines when compared to controls.

The GMA24 mutant mice display reduced phosphorus levels in blood by 38% in females and 53% in males. No other change was observed in this mutant line.

We started to map the mutations and identify a region of 18 cM and 29 cM on proximal chromosome 17 for the Cut




Figure 3 Mapping. For each identified line, mutant original C57BL/6J \times FVB F1 mutant mice (carrying heterozygous mutations induced by *N*-ethylnitrosourea and a mutated allele for *Gdf8*) were backcrossed to *Gdf8*^{-/-} FVB mice. Genomic DNA was isolated from the backcross progeny for genetic analyses. Genome-wide scanning with 60 microsatellite markers showed linkages between (a) GMA06 mutation and chromosome 13, (b) GMA24, GMA12 mutations and chromosome 9, (c) GMA11, CUT mutations and chromosome 17. No other regions of the genome provided evidence of linkage. Markers are shown with their respective positions (cM) on the chromosomes. The black boxes represent FVB alleles and the white ones correspond to C57BL/6J \times FVB alleles. The number of progeny that inherited each haplotype is given below the boxes. The greyed box indicates the chromosomal interval bearing the mutation.

and GMA11 lines, respectively. We detected linkage to regions on chromosome 9 for GMA12 and GMA24. Subsequent genotyping of mutant animals in these regions localised GMA12 to a 29 cM interval flanked by D9Mit129 and D9Mit192 markers and to a 18 cM region from centromere to D9Mit205 for GMA24 (Figure 3).

Discussion

The current investigation focused on the development of an alternative approach to QTL mapping and its contribution to identify regions or genes controlling skeletomuscular development in cattle. QTL strategy is incontestably very powerful (Boichard *et al.*, 2003; Abe *et al.*, 2008) but extremely cumbersome and costly when dealing with large animals such as ruminants. Although recent developments in livestock genomics have revolutionised the mapping and the identification of QTL, the fine mapping remains a real challenge. The limiting step is not the number of genetic markers on a map, nor the knowledge of the DNA sequence of the detected region, but the functional properties of a given DNA segment. Thus, our goal is to get genomic and functional information on a specific DNA segment in other species, and especially in mouse, helping to dissect the exact molecular mechanism of the QTL. Our modifier screen is based on the identification of mutations directly or indirectly interfering with the *Gdf8* pathway altered in the cattle 'double-muscling' phenotype. *Gdf8* plays a crucial

role during myogenesis but also in bone development and morphogenesis, as it has recently been revealed (Hamrick *et al.*, 2007; Kellum *et al.*, 2009; Elkasrawy and Hamrick, 2010). In this genetic context, we identify a greater number of mutations affecting the skeletomuscular system than in a wild type setting (www.helmholtz-muenchen.de/en/ieg/group-functional-genetics/enu-screen/mutants-generated/index.html; www.mousegenome.bcm.tmc.edu/ENU/ENUMutantSources.asp). The subtle differences that we have found show the power of our strategy. The myostatin gene is located on chromosome 1. None of our identified mutations lies on this chromosome, showing that we have isolated dominant mutations acting with the *Gdf8* locus. Fine mapping is still in progress, and does not allow us to discriminate between a dominant mutation affecting an already known molecular partner of *Gdf8* or an unknown gene directly or indirectly interacting with *Gdf8*. The GMA06 and GMA45 lines are of high interest. Although these lines are currently under investigation, our preliminary phenotypic characterisation show that the hypertrophy in GMA06 mutants is more pronounced than in *Gdf8* knockout mice, and even more marked if the GMA06 mice are on a *Gdf8*^{-/-} genetic background. Further analyses are required to dissect the underlying mechanisms of these differences. Many studies have detected bovine QTL for both dairy and beef traits. Although some QTL for growth and carcass traits have been identified on chromosome 20, the ortholog of mouse chromosome 13,

these QTL only show either a suggestive level of linkage or a large interval of linkage (<http://www.genome.iastate.edu/cgi-bin/QTLdb/index>; <http://genomes.sapac.edu.au/bovineqtl/>). Fine mapping of these regions on BTA20 is still needed. However, once the role of a highlighted gene will be validated in our mouse model, the corresponding orthologous region in cattle will be defined based on the bovine sequence. It is also interesting to note that we found in our screen a large number of mutants with skeletal defects. These morphological abnormalities are more severe in homozygous *Gdf8*^{-/-} mice, consistent with the role of *Gdf8* in bone development (Hamrick *et al.*, 2007; Kellum *et al.*, 2009). The mechanisms by which myostatin regulates bone formation are not well understood, but it is clear that myostatin has direct effects on the proliferation and differentiation of mesenchymal stem cells (Rebbapragada *et al.*, 2003; Artaza *et al.*, 2005; Guo *et al.*, 2008). Our new mouse models might help to unravel the exact role of myostatin in regulating osteogenesis. The improvement of the livestock is a basic issue, by itself vital. It will ensure a safer and healthier food supply. It is undeniable that the increased understanding of gene's function through mutagenesis programmes in the mouse is bringing a wealth of information that, when combined with comparative genomics, can accelerate our knowledge of the bovine genome. Finally, our approach might give clues to the origin of the diversity of the double-muscling phenotype. On the basis of the similar phenotype induced by the *Gdf8* knockout in the mouse, our sensitised screen will identify modifiers of the muscular phenotype in a pure genetic background.

Acknowledgements

We are indebted to Professor L. Grobet for kindly providing the *Gdf8* mice. We thank K. Pasquier, S. Desforges for help with animal manipulation. We are grateful to A. Germot and D. Petit for critical reading of the manuscript. We sincerely thank Professor R. Julien for his continuous support and interest in our study. This study was supported by the French National Institute for Agricultural Research and by the Limousin Regional Council.

References

Abe T, Saburi J, Hasebe H, Nakagawa T, Kawamura T, Saito K, Nade T, Misumi S, Okumura T, Kuchida K, Hayashi T, Nakane S, Mitsuhashi T, Nirasawa K, Sugimoto Y and Kobayashi E 2008. Bovine quantitative trait loci analysis for growth, carcass, and meat quality traits in an F2 population from a cross between Japanese Black and Limousin. *Journal of Animal Sciences* 86, 2821–2832.

Artaza JN, Bhasin S, Magee TR, Reisz-Porszasz S, Shen R, Groome NP, Meerasahib MF and Gonzalez-Cadavid NF 2005. Myostatin inhibits myogenesis and promotes adipogenesis in C3H10T(1/2) mesenchymal multipotent cells. *Endocrinology* 146, 3547–3557.

Arthur PF 1995. Double muscling in cattle: a review. *Australian Journal of Comment: agricultural research* 46, 1493–1515.

Bach EA, Vincent S, Zeidler MP and Perrimon N 2003. A sensitized genetic screen to identify novel regulators and components of the *Drosophila* Janus Kinase/signal transducer and activator of transcription pathway. *Genetics* 165, 1149–1166.

Bellinge RH, Liberles DA, Iaschi SP, O'Brien PA and Tay GK 2005. Myostatin and its implications on animal breeding: a review. *Animal Genetics* 36, 1–6.

Besson V, Nalesso V, Herpin A, Bizot JC, Messaddeq N, Romand R, Puech A, Blanquet V and Herault Y 2005. Training and aging modulate the loss-of-balance phenotype observed in a new ENU-induced allele of Otopetrin1. *Biology of Cell* 97, 787–798.

Boichard D, Grohs C, Bourgeois F, Cerqueira F, Faugeras R, Neau A, Rupp R, Amigues Y, Boscher MY and Leveziel H 2003. Detection of genes influencing economic traits in three French dairy cattle breeds. *Genetics Selection Evolution* 35, 77–101.

Brown SD, Chambon P and de Angelis MH 2005. EMPReSS: standardized phenotype screens for functional annotation of the mouse genome. *Nature Genetics* 37, 1155.

Buac K, Watkins-Chow DE, Loftus SK, Larson DM, Incao A, Gibney G and Pavan WJ 2008. A Sox10 expression screen identifies an amino acid essential for Erbb3 function. *PLoS Genetics* 4, e1000177.

Carpinelli MR, Hilton DJ, Metcalf D, Antonchuk JL, Hyland CD, Mifsud SL, Di Rago L, Hilton AA, Willson TA, Roberts AW, Ramsay RG, Nicola NA and Alexander WS 2004. Suppressor screen in *Mpl*^{-/-} mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signalling. *Proceedings of the National Academy of Sciences USA* 101, 6553–6558.

Clark AT, Goldowitz D, Takahashi JS, Vitaterna MH, Siepka SM, Peters LL, Frankel WN, Carlson GA, Rossant J, Nadeau JH and Justice MJ 2004. Implementing large-scale ENU mutagenesis screens in North America. *Genetica* 122, 51–64.

Cordes SP 2005. N-ethyl-N-nitrosourea mutagenesis: boarding the mouse mutant express. *Microbiology and Molecular Biology Reviews* 69, 426–439.

Drögemüller C, Distl O and Leeb T 2001. Partial deletion of the bovine ED1 gene causes anhidrotic ectodermal dysplasia in cattle. *Genome Research* 11, 1699–1705.

Duchesne A, Gautier M, Chadi S, Grohs C, Floriot S, Gallard Y, Caste G, Ducos A and Eggen A 2006. Identification of a doublet missense substitution in the bovine *LRP4* gene as a candidate causal mutation for syndactyly in Holstein cattle. *Genomics* 88, 610–621.

Elkasrawy MN and Hamrick MW 2010. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. *Journal of Musculoskeletal and Neuronal Interactions* 10, 56–63.

Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R and Georges M 1997. A deletion in the bovine myostatin gene causes the double-muscling phenotype in cattle. *Nature Genetics* 17, 71–74.

Grobet L, Poncelet D, Royo LJ, Brouwers B, Pirottin D, Michaux C, Menissier F, Zanotti M, Dunner S and Georges M 1998. Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle. *Mammalian Genome* 9, 210–213.

Grobet L, Pirottin D, Farnir F, Poncelet D, Royo LJ, Brouwers B, Christians E, Desmecht D, Coignoul F, Kahn R and Georges M 2003. Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. *Genesis* 35, 227–238.

Guenet JL 2004. Chemical mutagenesis of the mouse genome: an overview. *Genetica* 122, 9–24.

Guo W, Flanagan J, Jasuja R, Kirkland J, Jiang L and Bhasin S 2008. The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signalling pathways. *Journal of Biological Chemistry* 283, 9136–9145.

Hamrick MW, Shi X, Zhang W, Pennington C, Thakore H, Haque M, Kang B, Isales CM, Fulzele S and Wenger KH 2007. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. *Bone* 40, 1544–1553.

Karim FD, Chang HC, Therrien M, Wassarman DA, Laverty T and Rubin GM 1996. A screen for genes that function downstream of Ras1 during *Drosophila* eye development. *Genetics* 143, 315–329.

Kellum E, Starr H, Arounleut P, Immel D, Fulzele S, Wenger K and Hamrick MW 2009. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. *Bone* 44, 17–23.

Kunieda T, Ide H, Nakagiri M, Yoneda K, Konfortov B and Ogawa H 2000. Localization of the locus responsible for Chediak–Higashi syndrome in cattle to bovine chromosome. *Animal Genetics* 31, 87–90.

- Loo S, Laurenson P, Foss M, Dillin A and Rine J 1995. Roles of ABF1, NPL3, and YCL54 in silencing in *Saccharomyces cerevisiae*. *Genetics* 141, 889–902.
- McPherron AC and Lee SJ 1997. Double muscling in cattle due to mutations in the myostatin gene. *Proceedings of the National Academy of Sciences USA* 94, 12457–12461.
- McPherron AC, Lawler AM and Lee SJ 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature* 387, 83–90.
- Rafferty LA, Twombly V, Wharton K and Gelbart WM 1995. Genetic screens to identify elements of the decapentaplegic signalling pathway in *Drosophila*. *Genetics* 139, 241–254.
- Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ and Attisano L 2003. Myostatin signals through a transforming growth factor beta-like signalling pathway to block adipogenesis. *Molecular and Cellular Biology* 23, 7230–7242.
- Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ and Martin JE 1997. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. *Mammalian Genome* 8, 711–713.
- Rubio-Aliaga I, Soewarto D, Wagner S, Klaften M, Fuchs H, Kalaydjiev S, Busch DH, Klempt M, Rathkolb B, Wolf E, Abe K, Zeiser S, Przemek GK, Beckers J and de Angelis MH 2007. A genetic screen for modifiers of the delta1-dependent notch signalling function in the mouse. *Genetics* 175, 1451–1463.
- Satterthwaite AB, Willis F, Kanchanastit P, Fruman D, Cantley LC, Helgason CD, Humphries RK, Lowell CA, Simon M, Leitges M, Tarakhovsky A, Tedder TF, Lesche R, Wu H and Witte ON 2000. A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. *Proceedings of the National Academy of Sciences USA* 97, 6687–6692.
- Simon MA, Bowtell DD, Dodson GS, Lavery TR and Rubin GM 1991. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signalling by the sevenless protein tyrosine kinase. *Cell* 67, 701–716.
- Soewarto D, Blanquet V and de Angelis Hrabec M 2003. Random ENU mutagenesis. *Methods of Molecular Biology* 209, 249–266.
- Soewarto D, Klaften M and Rubio-Aliaga I 2009. Features and strategies of ENU mouse mutagenesis. *Current Pharmaceutical Biotechnology* 10, 198–213.
- Takeda H, Takami M, Oguni T, Tsuji T, Yoneda K, Sato H, Ihara N, Itoh T, Kata SR, Mishina Y, Womack JE, Moritomo Y, Sugimoto Y and Kunieda T 2002. Positional cloning of the gene LIMBIN responsible for bovine chondro-dysplastic dwarfism. *Proceedings of the National Academy of Sciences USA* 99, 10549–10554.